Almac continues biocatalysis business growth with a further $4m R&D investment

11-Oct-2010 - United Kingdom

The need for green, economic, robust and scaleable processes for the synthesis of chiral APIs and intermediates prompted Almacto build and fully integrate a biocatalysis group into its service portfolio. Last year Almac launched carbonyl reductase, transaminase, hydrolase, nitrilase, and nitrile hydratase enzyme screening kits and is continuing to both advance the biocatalysis business – and to broaden application of its biocatalysis expertise with a further $4m R&D investment.

The investment will be used primarily to focus around discovery of new biocatalytic platforms that can be rapidly implemented and scaled delivering cost effective processes to chiral intermediates. Other areas of research will investigate hyper-activation of biocatalysts reducing enzyme loadings, as well as development of efficient and robust drivers for cofactor recycle and problems with equilibriums.

As anticipated, the business has advanced from the sale of enzyme screening kits, then to screening and optimising custom transformations, and finally to the supply of 10s then 100s of kgs of chiral intermediates.

For example, preliminary screening was carried out to demonstrate that a carbonyl reductase (CRED) bioreduction could replace a resolution for the preparation of a chiral alcohol. Having identified a CRED at small scale, Almac prepared a hundred grams of the chiral alcohol and integrated it into the API process development programme.

The next step was to manufacture 30 kgs for incorporation into the GMP API manufacture for Phase I clinical trials.

The rapid scale-up from biocatalyst screening has been the critical success factor for the recent paradigm shift to bioprocessing acceptance for the synthesis of APIs and fine chemicals.

https://www.bionity.com/en/news/124083/almac-continues-biocatalysis-business-growth-with-a-further-4m-r-d-investment.html